Puma Biotechnology (PBYI) Operating Expenses (2010 - 2026)

Puma Biotechnology's Operating Expenses history runs 17 years deep, the most recent figure standing at $48.6 million for Q1 2026.

• Quarterly Operating Expenses rose 15.75% year-over-year to $48.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $197.7 million (up 1.14% YoY) and the FY2025 annual result came in at $191.1 million, down 4.23% from the prior year.
• Operating Expenses was $48.6 million for Q1 2026 at Puma Biotechnology, down from $58.3 million in the prior quarter.
• Across five years, Operating Expenses topped out at $58.5 million in Q3 2024 and bottomed at $42.0 million in Q1 2025.
• A 5-year average of $49.8 million and a median of $48.4 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses sank 40.42% — and 2025, when it climbed 27.64%.
• Puma Biotechnology's Operating Expenses stood at $55.7 million in 2022, then grew by 3.09% to $57.4 million in 2023, then decreased by 20.33% to $45.7 million in 2024, then rose by 27.64% to $58.3 million in 2025, then declined by 16.63% to $48.6 million in 2026.
• Business Quant data shows PBYI's Operating Expenses at $48.6 million in Q1 2026, $58.3 million in Q4 2025, and $44.9 million in Q3 2025.